Hansa Biopharma AB (publ) announced that the current chair Ulf Wiinberg has chosen to not stand for re-election.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.46 SEK | +1.48% |
|
-7.49% | +62.06% |
May. 31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
May. 31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.06% | 256M | |
+34.14% | 51.51B | |
-6.54% | 39.03B | |
+34.92% | 38.91B | |
-12.11% | 26.68B | |
+12.62% | 26.13B | |
-13.43% | 19.91B | |
+43.73% | 13.71B | |
+31.81% | 12.38B | |
-4.54% | 11.74B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB's Current Chair Ulf Wiinberg Has Chosen to Not Stand for Re-Election